Toritani, Kenichiro
Kimura, Hideaki
Otani, Masako
Fukuoka, Hironori
Kunisaki, Reiko
Watanabe, Jun
Ishibe, Atsushi
Misumi, Toshihiro
Inayama, Yoshiaki
Endo, Itaru
Article History
Received: 10 May 2022
Accepted: 18 November 2022
First Online: 27 November 2022
Competing interests
: Hideaki Kimura reports receiving personal fees from Mitsubishi Tanabe Pharma, EA Pharma, ZERIA Pharmaceuticals and Janssen Pharmaceuticals while conducting the study. Reiko Kunisaki reports receiving research grants or personal fees from AbbVie GK, Janssen Pharmaceutical K.K., JIMRO Co,. Ltd, Kyorin Pharmaceutical Co., Ltd, Kyowa Hakko Kirin Co., Ltd, Nippon Kayaku Co.,Ltd, Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Co Ltd and Zeria Pharmaceutical Co. Ltd while conducting the study. Jun Watanabe reports receiving honoraria for lectures from Johnson and Johnson, Medtronic and Eli Lilly, and receiving research funding from Medtronic, AMCO and TERUMO outside the submitted work. Itaru Endo reports receiving personal fees from ASAHI KASEI PHARMA CORPORATION while conducting the study. Kenichiro Toritani, Masako Otani, Hironori Fukuoka, Atsushi Ishibe, Toshihiro Misumi, and Yoshiaki Inayama have no financial disclosures or conflicts of interest.